Clinical trial · Observational
Treatment Duration of IPA
Invasive Pulmonary Aspergillosis Treatment Duration of Posaconazole-initiated Antifungal Strategy in Patients with Hematological Malignancies: a Prospective, Single-center Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to identify the duration of posaconazole-initiated antifungal treatment for IPA in patients with hematological malignancies and to explore the value of monitoring immune factors and cells in IPA treatment in order to assess practices in IPA management in Chinese hematology patients including tools to evaluate duration and discontinuation. The main question it aims to answer is: Does any indicators that could be used to guide the duration of IPA treatment? Does immune factors have value in monitoring IPA treatment? We will not do any interventions to participants. Participants will be monitored routinely for their clinical characteristics, microbiological test( including G/GM Test, Blood culture), Imaging examination, Blood routine, the number and function of immune cells, cytokines(IL-1β/IL-2/IL-4/IL-8/IL-10/IL-12/IL-17/IFN-α/IFN-γ/TNF-α)， and we will collect these datas for analysing.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Antifungal Therapy | — | UNRESOLVED | — |
| Invasive Aspergillosis | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The duration of posaconazole-initiated antifungal treatment therapy for IPA in patients with hematological malignancies
- timeFrame
- 12 weeks after discontinuation of posaconazole-initiated antifungal therapy
- description
- The primary outcome is the duration of posaconazole-initiated antifungal treatment therapy for IPA in patients with hematological malignancies
Secondary outcomes (7)
- measure
- All-cause mortality on 2/4/8 /12 weeks after discontinuation
- timeFrame
- 12 weeks after discontinuation of posaconazole-initiated antifungal therapy
- description
- The mortality of patients died for any reasons on 2/4/8/12 weeks after discontinuation of antifungal therapy
- measure
- IFI-free survival rate on 2/4/8/12 weeks after discontinuation
- timeFrame
- 12 weeks after discontinuation of posaconazole-initiated antifungal therapy
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Informed consent form signed 2. Patient with hematological malignancies 3. Patients with posaconazole-initiated antifungal therapy 4. Treatment duration ≥12w Exclusion Criteria: 1. Refuse to enroll 2. Pregnancy or breastfeeding women 3. Are expected to survive no more than 72 h 4. Fungal or mycobacterial lung co infection at time of IPA diagnosis 5. Hematological malignancy with lung location 6. Disseminated aspergillosis (lung and sinus aspergillosis can be included)
References
Publications (0)
Data not yet available